✦ LIBER ✦

Managing inadequate responses to frontline treatment of chronic myeloid leukemia: A case-based review

✍ Scribed by Bixby, Dale L.

Book ID: 122108349
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 502 KB
Volume: 39
Category: Article
ISSN: 0305-7372
DOI: 10.1016/j.ctrv.2012.04.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Failure of a non-authorized copy product

Failure of a non-authorized copy product to maintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report

✍ Hadi Alphonse Goubran 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 163 KB

Study protocol of the RAND-study: a mult

Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia

✍ Boons, Christel CLM; Swart, Eleonora L; Timmers, Lonneke; van de Ven, Peter M; J 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 178 KB

Chronic Myeloid Leukemia Philadelphia Ch

Chronic Myeloid Leukemia Philadelphia Chromosome Positive (CML Ph+) With Imatinib (IM) Intolerance or Resistant Disease - Response to Thalidomide (TALI) Treatment - Preliminary Report of a Serial of Cases With Encouraging Results

✍ Hurtado-Monroy, Rafael; Vargas-Viveros, Pablo; Cervera-Ceballos, Eduardo; Cruz-V 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 233 KB

Is it possible to discontinue imatinib m

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o

PCN150 SYSTEMATIC LITERATURE REVIEW ON T

PCN150 SYSTEMATIC LITERATURE REVIEW ON THE INTER AND INTRA LABORATORY VARIABILITY OF MOLECULAR TESTING OF RESPONSE TO TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS AND THE ASSOCIATED COSTS AND COST-EFFECTIVENESS

✍ M Ratcliffe; PE Hudson; D Ossa 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Adherence to the standard dose of imatin

Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia

✍ Chikashi Yoshida; Takuya Komeno; Mitsuo Hori; Tomofumi Kimura; Masami Fujii; Yas 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 162 KB